Latest news with #LicenseApplication
Business Wire
13-05-2025
- Business
- Business Wire
Oklo Completes Site Characterization Borehole Drilling for First Powerhouse
IDAHO FALLS, Idaho--(BUSINESS WIRE)--Oklo successfully completed borehole drilling for site characterization work at the Idaho National Laboratory site for its first Aurora Powerhouse. This milestone marks a significant step forward in the development and future construction of the facility. The completed work included the drilling of several boreholes to support comprehensive geotechnical assessments of subsurface conditions. These efforts help with validating site suitability, informing detailed engineering design, and securing the necessary permits for construction. 'The completion of this drilling campaign highlights our team's ability to execute through the early stages of site development,' said Jacob DeWitte, co-founder and CEO at Oklo. 'With this work completed, we are well-positioned to continue making progress on licensing, infrastructure development, and ultimately, the groundbreaking of our first Aurora powerhouse.' The site characterization phase involved collaboration with leading geotechnical experts to ensure all data collection met regulatory and industry standards. The insights gathered will guide foundation design, seismic safety measures, and other site suitability assessments. These geotechnical analyses will be integrated into Oklo's Combined License Application (COLA) to the U.S. Nuclear Regulatory Commission. Oklo's COLA covers the design, construction, and operation of the Aurora powerhouse, enabling a streamlined and efficient regulatory review process. Once approved, the license will authorize Oklo to construct and operate the plant. About Oklo Inc.: Oklo Inc. is developing fast fission power plants to deliver clean, reliable, and affordable energy at scale; establishing a domestic supply chain for critical radioisotopes; and advancing nuclear fuel recycling to convert nuclear waste into clean energy. Oklo was the first to receive a site use permit from the U.S. Department of Energy for a commercial advanced fission plant, was awarded fuel from Idaho National Laboratory, and submitted the first custom combined license application for an advanced reactor to the U.S. Nuclear Regulatory Commission. Oklo is also developing advanced fuel recycling technologies in collaboration with the U.S. Department of Energy and national laboratories. Forward-Looking Statements This press release includes statements that express Oklo's opinions, expectations, objectives, beliefs, plans, intentions, strategies, assumptions, forecasts or projections regarding future events or future results and therefore are, or may be deemed to be, 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' or, in each case, their negative or other variations or comparable terminology, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning, among other things, the benefits of the proposed acquisition, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which Oklo operates. Such forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. As a result of a number of known and unknown risks and uncertainties, the actual results or performance of Oklo may be materially different from those expressed or implied by these forward-looking statements. The following important risk factors could affect Oklo's future results and cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements: risks related to the deployment of Oklo's powerhouses; the risk that Oklo is pursuing an emerging market, with no commercial project operating, regulatory uncertainties; the potential need for financing to construct plants, market, financial, political and legal conditions; the effects of competition; the risk that an agreement with Atomic Alchemy and the proposed acquisition thereof do not materialize or fail to produce the expected benefits; changes in applicable laws or regulations; and the outcome of any government and regulatory proceedings and investigations and inquiries. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties of the other documents filed by Oklo from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release and in any document incorporated by reference are based on current expectations and beliefs concerning future developments and their potential effects on Oklo. There can be no assurance that future developments affecting Oklo will be those that Oklo has anticipated. Oklo undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Yahoo
07-05-2025
- Business
- Yahoo
Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting
Merck recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, contributing to a 6% price increase over the past week. The supplemental Biologics License Application under FDA review further highlights KEYTRUDA's significance in Merck's portfolio. This comes amid a broader market upswing, as the S&P 500 and Nasdaq climbed overall. While Merck's earnings were steady, the lawsuit from Halozyme presents a potential challenge ahead. Overall, Merck seems to align positively with broader market trends. We've identified 1 possible red flag with Merck and understanding the impact should be part of your investment process. NYSE:MRK Earnings Per Share Growth as at Apr 2025 These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent success of Merck's KEYNOTE-689 trial and its potential to enhance investor confidence could further strengthen the company's narrative around robust pipeline growth. This aligns well with Merck's strategy of driving future success in its oncology and cardiometabolic sectors through innovative launches like WINREVAIR. Despite short-term setbacks, such as the paused shipments of GARDASIL in China, Merck's long-term growth outlook remains positive, as these developments may bolster revenue and earnings forecasts significantly. Over the past five years, Merck's total shareholder return, inclusive of share price appreciation and dividends, was 31.62%. In the recent year, however, Merck underperformed, with the US Pharmaceuticals industry seeing a 1.3% increase in returns, while Merck struggled to keep pace amidst market challenges. Despite these near-term hurdles, the market response to the positive trial results has been promising, pushing Merck's current share price toward the consensus analyst price target of US$108.98, suggesting potential upside. Insights from our recent valuation report point to the potential undervaluation of Merck shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
